Here we demonstrate that TMPRSS2-ERG fusion and TP53 mutation / deletion co-occur in PCa patient specimens and this co-occurrence accelerates prostatic oncogenesis. The gene discussed is TMPRSS2; the disease is posterior cortical atrophy.